摘要
神经系统自身免疫病具有较高发病率和死亡率,如早期诊断具有可治性.自身抗体检测有可能成为该类疾病诊断、判断病情进展及预后、疗效评估重要的实验室指标.随着新的理论知识和实验室检测方法发展,着力研究开发基于免疫疾病发病机制的、高灵敏度与高特异性的神经系统自身抗体检测已迫在眉睫.为实现这一目标,我们需要加强神经系统自身免疫病发病机制与临床转化研究,开展临床多中心随机双盲试验来正确评价自身抗体的临床应用价值,并加快这些自身抗体检测项目的应用和推广.
Autoimmune neurological diseases have a high morbidity and mortality,but are treatable if diagnosed earlier.Many auto-antibodies may become important laboratory biomarkers for the diagnosis,evaluating severity,prognosis,and even reflecting treatment response,of these diseases.With the development of new knowledge and diagnostic technology,there is a pending need for discovering new pathogenesis-based biomarkers with high sensitivity and specificity on autoimmune diseases of the nervous system.To fulfill this goal,the pathogenesis as well as translational studies in autoimmune diseases of the nervous system are highly warranted.Multi-center randomized double-blinded clinical trials are also necessary to appropriately evaluate the clinical value of these auto-antibodies.W henever possible,these validated autoantibody assays are readily encouraged to perform and popularize these methods in clinical practice.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2014年第8期573-576,共4页
Chinese Journal of Laboratory Medicine
关键词
神经系统自身免疫疾病
自身抗体
多中心研究
Autoimmune diseases of the nervous system
Autoantibodies
Multicenter study